New drug cocktail shows promise in slowing rare sarcoma
NCT ID NCT04028063
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding two immunotherapy drugs (zalifrelimab and balstilimab) to standard chemotherapy (doxorubicin) can help control advanced or metastatic soft tissue sarcoma for longer. About 65 adults with sarcoma that cannot be removed by surgery will receive the combination. The main goal is to see if the cancer stays stable for at least 6 months, compared to historical results with chemotherapy alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOFT TISSUE SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Colorado Hospital
Aurora, Colorado, 80045, United States